Which company does brigatinib/brigatinib come from?

Brigatinib is a drug that targets non-small cell lung cancer (NSCLC) caused by ALK (tyrosine kinase) mutations. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Co., Ltd. In April 2017, it received accelerated approval from the U.S. Food and Drug Administration (FDA) for metastatic non-small cell lung cancer; in 2020, it was approved as a first-line treatment for patients with ALK-positive metastatic non-small cell lung cancer and is sold under the trade name Alunbrig.

Brigatinib, as an innovative drug from Ariad Pharmaceuticals, has important clinical application value in the treatment of non-small cell lung cancer caused by ALK mutations. This drug inhibits the activation of ALK fusion protein, thereby blocking the proliferation and growth of tumor cells, thereby achieving the purpose of treating lung cancer. Clinical trial results show that brigatinib can significantly prolong the progression-free survival of patients with non-small cell lung cancer and still has a certain efficacy in drug resistance. This makes brigatinib one of the important choices in the treatment of non-small cell lung cancer.

Brigatinib is only available by prescription, and treatment must be started and supervised by a doctor experienced in using cancer drugs. Before starting treatment, doctors should test patients' cancers to confirm that they have genetic changes that affectALK ("ALK-positive" status). This medicine is available in 30 mg, 90 mg and 180 mg tablets. Treatment can continue as long as the patient benefits from it. If side effects occur, your doctor may reduce your dose or temporarily stop treatment. In some cases, treatment should be stopped permanently.